

## NEWS RELEASE

### Teijin Launches Teijin Meguro Institute to Strengthen Functional Food Ingredients Business

Tokyo, Japan, October 3, 2022 --- [Teijin Limited](#) announced today its launch of the [Teijin Meguro Institute Co., Ltd.](#) to strengthen the company's development and manufacture of probiotics for use in functional foods. The new firm will provide functional food ingredients that meet the demands of health-conscious consumers by leveraging its predecessor's expertise in probiotics, which are microorganisms that benefit human health by improving the balance of intestinal lactic acid bacteria, etc. and the prebiotics that feed them.

Teijin Meguro Institute, the new wholly owned subsidiary of Teijin Limited, has inherited the personnel and equipment of its predecessor, Meguro Institute. The former company was established in 1925 as the Osaka Experimental Therapy Institute by the late Dr. Yosaburo Meguro, an abacteriologist and immunologist who studied at the Kitasato Institute and the Pasteur Institute. In 1937, the company name was changed to Meguro Institute, and it manufactured, sold and handled outsourced business involving lactic acid bacteria and *Bacillus subtilis* natto for use in pharmaceuticals, functional foods and feed additives backed by its excellent expertise in culturing bacteria, manufacturing method and stable supply. In August, Teijin signed a share-transfer agreement with Maruishi Pharmaceutical Co., Ltd., the parent company of Meguro Research Institute, and subsequently received 100% of the firm's shares. The new company, while continuing to conduct research, manufacturing and sales of lactic acid bacteria and *Bacillus subtilis* natto, also will work to commercialize promising microorganisms currently being developed by Teijin.

The newly appointed president of Teijin Meguro Institute is Takanori Miyoshi, who has engaged in basic research into polymer materials since joining Teijin in 1992 as well as research and development of functional-food ingredients since 2013.

#### Overview of Teijin Meguro Institute

Official Name	Teijin Meguro Institute Co., Ltd.
Head Office	2-6-4 Fushimimachi, Chuo-ku, Osaka, Japan
President	Takanori Miyoshi
Capital	JPY 35.2 million
Employees	24 (October 2022)
Business	Manufacture, sale and import of ingredients for pharmaceuticals, functional foods, feed additives, etc.
Sales	JPY 730 million in FY2021 (Meguro Institute Co., Ltd.)

Teijin expects to enhance the probiotics division of its functional food ingredients business by merging its own research, development and marketing capabilities with the technologies, knowhow and sales network of Teijin Meguro Institute. In conjunction with the launch, Teijin has changed the name of its "Functional Food Ingredient Business Development Project" to the "Biolier Division." "Biolier" originally is Teijin's functional food ingredient business tradename in Japan emphasizing its status as one of a few companies involved with synbiotics, which synergistically combine the functions of

prebiotics and probiotics. Going forward, Teijin expects to accelerate the growth of its functional food ingredients line, part of the company's overall healthcare business, under a mission of enhancing human quality of life to help people worldwide enjoy fulfilling lives from birth to their final days.

Teijin's prebiotics lineup in Japan includes *BARLEYmax*<sup>™</sup> super barley sold since 2016 and water-soluble dietary fiber sold since 2018. In 2020, Teijin expanded into probiotics and signed a sales agency agreement with [Chr. Hansen Holding A/S](#), a leading supplier of probiotics, to sell materials and products such as lactic acid bacteria and bifidobacteria. In addition, Teijin created the "*Biolier*" tradename in Japan in 2020 for its entire functional food ingredient lineup to help position the company as a "bio sommelier" backed by scientific evidence and now uses "*Biolier*" in its new business division name to show the company's intention to expand its related business globally.

In recent years, the market for lactic-acid bacteria, bifidobacteria and other probiotics has expanded rapidly amid the general public's growing interest in immunity due to the COVID-19 pandemic. The global market, valued at roughly USD 3.5 billion in 2021, is expected to surpass USD 6 billion by 2028 according to a report issued by Insight Partners on June 17.

### **About the Teijin Group**

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement "Human Chemistry, Human Solutions," Teijin aims to be a company that supports the society of the future. The group comprises some 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2022.

### **Press Contact**

Corporate Communications

Teijin Limited

[pr@teijin.co.jp](mailto:pr@teijin.co.jp)